Quantum-Si Inc
No enriched coverage for $QSI in the last 7 days.
No SEC Form 4 filings for $QSI in the last 30 days.
See all $QSI insider activity →Quantum-Si (NASDAQ:QSI) reported Q2 2026 revenue of $344,000, down from $591,000 a year earlier, and a Q2 net loss of $23.5 million. The company said Proteus launch timing is revised to early 2027, with initial detection of 19 or 20 amino acids. It expects about $12 million annual operating-expense savings and full-year 2026 revenue near $1 million.
Quantum-Si Incorporated (QSI) reported Q2 adjusted EPS loss of $0.11, better than the Zacks Consensus loss of $0.13. Revenue was $0.34 million, up 4.24% versus the estimate, down from $0.59 million a year earlier. The article cites a Zacks Rank #3 (Hold) and notes upcoming consensus for the next quarter EPS of -$0.13 on $0.27 million revenue.
Quantum-Si Inc. (QSI) reported Q2 2026 revenue of $344,000, above an analyst estimate of $305,020. Diluted EPS was -$0.11, slightly better than expected. The company posted gross profit of $172,000 and an operating loss of $25.6 million, with net loss of $23.5 million. Cash was $23.7 million. Shares fell 1.19% after the release.
Recent QSI coverage spans earnings, financial news and corporate actions.
The call updates Proteus execution timeline and expected amino-acid detection range, alongside cash runway and cost-savings timing.
The print is a modest positive versus consensus, but the article flags that near-term follow-through depends on management commentary and updated estimate revisions.
Earnings confirm continued losses and low revenue scale, likely keeping valuation and financing risk in focus.
The update shifts the commercialization timeline later while improving balance-sheet visibility via cost cuts, likely increasing dilution/financing risk sensitivity if milestones slip.
The filing shifts the commercialization timeline and reduces near-term burn via layoffs, changing the risk/reward around Proteus execution and funding needs.
alphai scores every news story that mentions QSI with an AI model for sentiment and relevance, and aggregates insider trades from Quantum-Si Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Quantum-Si (NASDAQ:QSI) reported Q2 2026 revenue of $344,000, down from $591,000 a year earlier, and a Q2 net loss of $23.5 million. The company said Proteus launch timing is revised to early 2027, with initial detection of 19 or 20 amino acids. It expects about $12 million annual operating-expense savings and full-year 2026 revenue near $1 million.
6 min readQuantum-Si Incorporated (QSI) reported Q2 adjusted EPS loss of $0.11, better than the Zacks Consensus loss of $0.13. Revenue was $0.34 million, up 4.24% versus the estimate, down from $0.59 million a year earlier. The article cites a Zacks Rank #3 (Hold) and notes upcoming consensus for the next quarter EPS of -$0.13 on $0.27 million revenue.
6 min readQuantum-Si Inc. (QSI) reported Q2 2026 revenue of $344,000, above an analyst estimate of $305,020. Diluted EPS was -$0.11, slightly better than expected. The company posted gross profit of $172,000 and an operating loss of $25.6 million, with net loss of $23.5 million. Cash was $23.7 million. Shares fell 1.19% after the release.
4 min readQuantum-Si (Nasdaq: QSI) reported Q2 2026 revenue of $344k during the Platinum-to-Proteus transition, down from $591k a year earlier. It updated the Proteus launch to Q2 2027, cut about 20% of staff, and expects annualized operating expense savings of about $12m. Cash runway extends to Q4 2028; cash and investments were $169.9m at June 30, 2026.
4 min readQuantum-Si Inc (QSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Quantum-Si Reports Second Quarter 2026 Financial Results and Provides Proteus™ Development Update Company updates anticipated commercial launch of Proteus to Q2 2027, cost-reduction actions expected to extend cash runway into Q4 2028 and highlights estimated new mark
6 min readQuantum-Si Inc. (QSI) faces a second Nasdaq delisting risk after its Class A shares closed below $1 for 30 straight business days, according to a July 24 SEC filing. Shares traded around 78 cents, down about 29% YTD. Nasdaq gives until Jan. 19, 2027 to regain compliance. Q1 revenue was $258,000 and net loss $21.7 million.
5 min readUAS Magazine reports multiple counter-drone developments. Lockheed Martin introduced MORFIUS X-Rotor, a reusable high-power microwave system it says can disable more than 50 drones per mission, with more testing and prototype production planned. It also cites Quantum Systems’ Japan proof-of-concept selection, Ondas’ $6.9M Australian Defence contract, and Axon Vision’s ForceField live-fire testing.
2 min readQuantum-Si Inc (QSI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ex101sdleaseagreement.htm EX-10.1 ex101sdleaseagreement EXHIBIT 10.1 LEASE Between STERLING CITY SCIENCE SOUTH DEVELOPMENT, LLC, a Delaware limited liability company as Landlord and QUANTUM-SI INCORPORATED, a Delaware corporation as Tenant For certain premises at 9955 P
4 min readQuantum-Si Inc.'s CFO, Jeffry R. Keyes, was granted 780,847 stock options with an exercise price of $0.976 per share, expiring in 2036, and 652,803 restricted stock units (RSUs). These awards are compensation grants, not open-market transactions, and are subject to multi-year vesting schedules contingent on his continued employment. Following these grants, Keyes directly holds 1,816,000 shares of Class A common stock.
2 min readQuantum-Si Inc.'s Chief Product Officer, John S. Vieceli, was granted new equity awards, including options to purchase 468,508 shares of Class A common stock and 391,681 restricted stock units (RSUs). These awards, effective March 12, 2026, will vest in equal quarterly installments starting June 20, 2026, contingent on his continued service. Following these grants, Vieceli directly holds 1,192,654 shares of Class A common stock, with the awards classified as compensation-related and not open-market transactions.
2 min read
